PTI 428

Drug Profile

PTI 428

Alternative Names: PTI-428

Latest Information Update: 10 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Proteostasis Therapeutics
  • Class Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cystic fibrosis

Highest Development Phases

  • Phase I/II Cystic fibrosis

Most Recent Events

  • 29 Jun 2017 Preliminary safety, efficacy and pharmacokinetic data from a phase I study in Cystic fibrosis released by Proteostasis Therapeutics
  • 21 Jun 2017 Proteostasis Therapeutics plans a Proof-of-concept trial for the triple combination proof of concept combining PTI 428, PTI 801 and PTI 808
  • 30 Mar 2017 Proteostasis Therapeutics plans a phase II trial for Cystic fibrosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top